Novo Nordisk A/S (NOVO-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novo Nordisk A/S (NOVO-B) has a cash flow conversion efficiency ratio of 0.039x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr7.62 Billion ≈ $1.19 Billion USD) by net assets (Dkr194.05 Billion ≈ $30.36 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Novo Nordisk A/S (NOVO-B) balance sheet quality index to measure how much of total assets are equity-financed.
Novo Nordisk A/S - Cash Flow Conversion Efficiency Trend (1990–2025)
This chart illustrates how Novo Nordisk A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NOVO-B cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Novo Nordisk A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novo Nordisk A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Deere & Company
NYSE:DE
|
-0.034x |
|
Deutsche Telekom AG
XETRA:DTE
|
0.117x |
|
Honeywell International Inc
NASDAQ:HON
|
0.076x |
|
AT&T Inc.
NYSE:T
|
0.059x |
|
Shandong Zhongji Electrical Equipment Co Ltd
SHE:300308
|
0.059x |
|
Southern Copper Corporation
NYSE:SCCO
|
0.143x |
|
Banco Santander S.A.
MC:SAN
|
0.719x |
|
Siemens Energy AG
F:ENR
|
0.272x |
Annual Cash Flow Conversion Efficiency for Novo Nordisk A/S (1990–2025)
The table below shows the annual cash flow conversion efficiency of Novo Nordisk A/S from 1990 to 2025. For the full company profile with market capitalisation and key ratios, see Novo Nordisk A/S market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Dkr194.05 Billion ≈ $30.36 Billion |
Dkr119.10 Billion ≈ $18.63 Billion |
0.614x | -27.20% |
| 2024-12-31 | Dkr143.49 Billion ≈ $22.45 Billion |
Dkr120.97 Billion ≈ $18.93 Billion |
0.843x | -17.51% |
| 2023-12-31 | Dkr106.56 Billion ≈ $16.67 Billion |
Dkr108.91 Billion ≈ $17.04 Billion |
1.022x | +8.16% |
| 2022-12-31 | Dkr83.49 Billion ≈ $13.06 Billion |
Dkr78.89 Billion ≈ $12.34 Billion |
0.945x | +21.54% |
| 2021-12-31 | Dkr70.75 Billion ≈ $11.07 Billion |
Dkr55.00 Billion ≈ $8.61 Billion |
0.777x | -5.24% |
| 2020-12-31 | Dkr63.33 Billion ≈ $9.91 Billion |
Dkr51.95 Billion ≈ $8.13 Billion |
0.820x | +1.00% |
| 2019-12-31 | Dkr57.59 Billion ≈ $9.01 Billion |
Dkr46.78 Billion ≈ $7.32 Billion |
0.812x | -5.62% |
| 2018-12-31 | Dkr51.84 Billion ≈ $8.11 Billion |
Dkr44.62 Billion ≈ $6.98 Billion |
0.861x | +4.14% |
| 2017-12-31 | Dkr49.81 Billion ≈ $7.79 Billion |
Dkr41.17 Billion ≈ $6.44 Billion |
0.826x | -22.57% |
| 2016-12-31 | Dkr45.27 Billion ≈ $7.08 Billion |
Dkr48.31 Billion ≈ $7.56 Billion |
1.067x | +30.93% |
| 2015-12-31 | Dkr46.97 Billion ≈ $7.35 Billion |
Dkr38.29 Billion ≈ $5.99 Billion |
0.815x | +3.64% |
| 2014-12-31 | Dkr40.29 Billion ≈ $6.30 Billion |
Dkr31.69 Billion ≈ $4.96 Billion |
0.787x | +29.06% |
| 2013-12-31 | Dkr42.57 Billion ≈ $6.66 Billion |
Dkr25.94 Billion ≈ $4.06 Billion |
0.609x | +11.47% |
| 2012-12-31 | Dkr40.63 Billion ≈ $6.36 Billion |
Dkr22.21 Billion ≈ $3.48 Billion |
0.547x | -4.21% |
| 2011-12-31 | Dkr37.45 Billion ≈ $5.86 Billion |
Dkr21.37 Billion ≈ $3.34 Billion |
0.571x | +7.21% |
| 2010-12-31 | Dkr36.97 Billion ≈ $5.78 Billion |
Dkr19.68 Billion ≈ $3.08 Billion |
0.532x | +23.71% |
| 2009-12-31 | Dkr35.73 Billion ≈ $5.59 Billion |
Dkr15.38 Billion ≈ $2.41 Billion |
0.430x | +10.31% |
| 2008-12-31 | Dkr33.06 Billion ≈ $5.17 Billion |
Dkr12.90 Billion ≈ $2.02 Billion |
0.390x | +25.74% |
| 2007-12-31 | Dkr32.22 Billion ≈ $5.04 Billion |
Dkr10.00 Billion ≈ $1.56 Billion |
0.310x | +20.76% |
| 2006-12-31 | Dkr30.13 Billion ≈ $4.71 Billion |
Dkr7.74 Billion ≈ $1.21 Billion |
0.257x | -18.51% |
| 2005-12-31 | Dkr27.59 Billion ≈ $4.32 Billion |
Dkr8.70 Billion ≈ $1.36 Billion |
0.315x | +10.07% |
| 2004-12-31 | Dkr26.69 Billion ≈ $4.18 Billion |
Dkr7.64 Billion ≈ $1.20 Billion |
0.286x | +17.27% |
| 2003-12-31 | Dkr25.29 Billion ≈ $3.96 Billion |
Dkr6.18 Billion ≈ $966.71 Million |
0.244x | +14.69% |
| 2002-12-31 | Dkr22.90 Billion ≈ $3.58 Billion |
Dkr4.88 Billion ≈ $762.97 Million |
0.213x | -0.77% |
| 2001-12-31 | Dkr20.08 Billion ≈ $3.14 Billion |
Dkr4.31 Billion ≈ $674.44 Million |
0.215x | -35.77% |
| 2000-12-31 | Dkr15.75 Billion ≈ $2.46 Billion |
Dkr5.26 Billion ≈ $823.26 Million |
0.334x | +71.52% |
| 1999-12-31 | Dkr18.63 Billion ≈ $2.91 Billion |
Dkr3.63 Billion ≈ $567.93 Million |
0.195x | +1.11% |
| 1998-12-31 | Dkr18.04 Billion ≈ $2.82 Billion |
Dkr3.48 Billion ≈ $543.78 Million |
0.193x | +15.51% |
| 1997-12-31 | Dkr18.17 Billion ≈ $2.84 Billion |
Dkr3.03 Billion ≈ $474.36 Million |
0.167x | +39.10% |
| 1996-12-31 | Dkr16.02 Billion ≈ $2.51 Billion |
Dkr1.92 Billion ≈ $300.66 Million |
0.120x | -31.64% |
| 1995-12-31 | Dkr14.42 Billion ≈ $2.26 Billion |
Dkr2.53 Billion ≈ $395.82 Million |
0.175x | -13.47% |
| 1994-12-31 | Dkr13.13 Billion ≈ $2.05 Billion |
Dkr2.66 Billion ≈ $416.62 Million |
0.203x | +26.76% |
| 1993-12-31 | Dkr11.95 Billion ≈ $1.87 Billion |
Dkr1.91 Billion ≈ $299.16 Million |
0.160x | +27.15% |
| 1992-12-31 | Dkr10.56 Billion ≈ $1.65 Billion |
Dkr1.33 Billion ≈ $207.76 Million |
0.126x | +0.76% |
| 1991-12-31 | Dkr9.50 Billion ≈ $1.49 Billion |
Dkr1.19 Billion ≈ $185.60 Million |
0.125x | -41.66% |
| 1990-12-31 | Dkr7.03 Billion ≈ $1.10 Billion |
Dkr1.50 Billion ≈ $235.32 Million |
0.214x | -- |
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products i… Read more